Incyte
As of the edition of 20 October 2026, Incyte runs 56 drugs, 8 of them marketed; it is on route A at 16 targets and on route B at 8 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Incyte was renamed in 2000.
The records place 9 company names in this family.
- INCYTE CORP: renamed in 2000
Drugs by status
| Status | Count |
|---|---|
| Marketed | 8 |
| Active | 18 |
| Went quiet | 4 |
| Stopped | 25 |
| Status not established | 1 |
| Total | 56 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Ruxolitinib | Ends 2029 (exclusivity) | 4 |
| Baricitinib | Ends 2032 (patent) | 4 |
| Retifanlimab | Ends 2035 (computed from the first US licence) | 1 |
| Ponatinib | Ends 2033 (patent) | 1 |
| Tafasitamab | Ends 2032 (computed from the first US licence) | 1 |
| Capmatinib | Ends 2032 (patent) | 1 |
| Pemigatinib | Ends 2040 (patent) | 3 |
| Axatilimab | Ends 2036 (computed from the first US licence) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 16 targets, route B at 8 targets.
All 24 rows on route A or B
In the product24 company-target rows on route A or B; 21 are not shown here, and no score is.
See all 24 targets where Incyte needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 131 trials led
- Skin and connective tissue: 89 trials led
- Immune system: 78 trials led